Sexual dysfunction has a significant impact on quality of life, personal relationships, self-esteem, and recovery, and it is a common cause for nonadherence or discontinuation of medication.
Takeda announced that the FDA has approved a labeling update for Trintellix to include new head-to-head clinical data comparing it to Lexapro for improving treatment-emergent sexual dysfunction.
Flibanserin can be safely added to a stable SSRI or SNRI regimen to treat hypoactive sexual desire disorder.
Men, including male physicians, are less likely than female physicians to seek medical treatment for their own health conditions.
Flibanserin may improve some measures of sexual dysfunction in premenopausal women.
A clinician should also rule out the possibility that the dysfunction stems from a co-occurring medical or psychiatric condition, or substance abuse.
Awareness of adolescents’ sexual history is essential in providing mental health treatment.
Researchers found that the brains of those with compulsive sexual behaviors “lit up” in the same way as drug addicts’ brains.
